Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma
The 3E2 antibody demonstrates high concordance with Abcam 28-8, offering a potential cost-effective alternative for PD-L1 detection with preliminary prognostic value in immunotherapy-treated LUAD patients. Further validation is required to confirm its clinical utility.
Authors
- Qingqing Xu (ORCID: https://orcid.org/0009-0007-2211-8535)
- J G Wang (ORCID: https://orcid.org/0000-0002-8578-9447)
- Xiaoyi Zhong
- Liqiao Hu (ORCID: https://orcid.org/0000-0003-3904-4070)
- Yan Zheng (ORCID: https://orcid.org/0000-0003-4877-7292)
- Zhidong Zhang (ORCID: https://orcid.org/0000-0002-6203-0171)
- Hui Jiang (ORCID: https://orcid.org/0000-0003-3972-1297)
- Fei Qu (ORCID: https://orcid.org/0000-0003-1679-9526)
- Xinyu Yang
- Qingqing Zhao
Institutions
- Jinan Central Hospital (CN)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s12885-025-14941-z
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province